Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04974398
Title A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Recruitment Enrolling by invitation
Gender both
Phase Phase III
Variant Requirements No
Sponsors Akeso

nasopharynx carcinoma


Cisplatin + Gemcitabine

AK105 + Cisplatin + Gemcitabine

Age Groups: child | adult | senior
Covered Countries USA

No variant requirements are available.